anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fluoxetine hydrochloride is a selective serotonin reuptake inhibitor for oral administration. It is designated (±)-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine hydrochloride and has the molecular formula of C17H18F3NO•HCl. Its molecular weight is 345.79. The structural formula is: 

Fluoxetine hydrochloride USP is a white to off-white crystalline powder. It is sparingly soluble in water and in dichloromethane; freely soluble in methanol and in alcohol. Practically insoluble in ether.

Each scored tablet contains fluoxetine hydrochloride equivalent to 60 mg (194 µmol) of fluoxetine. In addition, each scored tablet also contains the following inactive ingredients: croscarmellose sodium, hypromellose, polyethylene glycol, povidone, prosolv, pregelatinized starch, microcrystalline cellulose, magnesium stearate and titanium dioxide.
PROBLEM TO BE SOLVED: To prepare the subject pharmaceutical preparation capable of effective ly preventing cell adhesion by EDA associated with a disease such as fibrosis by using a material for inhibiting bond of αvβ5 integrin to fibronectin EDA caused in the presence of serum as an active ingredient. SOLUTION: This pharmaceutical preparation contains a material for inhibiting the bond of αvβ 5 integrin to fibronectin EDA caused in the presence of serum as an active ingredient. Preferably, the pharmaceutical preparation contains a material for inhibiting the bond of the αvβ5 integrin to the fibronectin EDA and vironectin of a component in the serum as an active ingredient. The inhibiting material preferably has its inhibitory activity larger than that of GRGDSP peptide. For example, an anti-EDA antibody, an anti-αvβ5 integrin antibody, etc., are cited. The daily dose of the objective pharmaceutical preparation is ordinary 0.1-50 mg per adult in the case of oral administration.
<P>PROBLEM TO BE SOLVED: To provide a compounding agent for a composition for external use slight in sticky feeling even if comprising a large amount of a polyhydric alcohol or saccharide, good in moist feeling of the skin, and high in moisturizing effect, and to provide the composition for external use.  <P>SOLUTION: The compounding agent for a composition for external use comprises a cellooligosaccharide with a structure of the formula(1)( wherein, n is 0-4 ). Specifically, in the compounding agent, the cellooligosaccharide is cellobiose. The composition for external use contains the above compounding agent. Another version of the composition for external use comprises the above compounding agent, a polyhydric alcohol and a saccharide.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
Systems and methods that automate the backup of specific patient related information to network attached, but segregated device. Each patient's information that is required for treatment (DICOM files) are automatically queried from the EHR databased and transferred using DICOM transactions to the workstation through specified TCP ports. The software automatically organizes and stores the files on a secure/encrypted USB drive. The software then leverages web-based application programming interfaces (APIs) to pull patient documents that are relevant for treatment. Finally, a treatment summary report is generated and stored along-side the EHR documents and DICOM files. In the event of a failure, the USB device can be removed and plugged into the treatment delivery devices to allow for treatment of patients under care.
Cholestatic liver diseases causes inflammation and fibrosis around bile ducts. However, the pathological mechanism has not been elucidated. Extracellular vesicles (EVs) are released from both the basolateral and apical sides of polarized biliary epithelial cells. We aimed to investigate the possibility that EVs released from the basolateral sides of biliary epithelial cells by bile acid stimulation induce inflammatory cells and fibrosis around bile ducts, and they may be involved in the pathogenesis of cholestatic liver disease. Human biliary epithelial cells (H69) were grown on cell culture inserts and stimulated with chenodeoxycholic acid + IFN-γ. Human THP-1-derived M1-macrophages, LX-2 cells, and KMST-6 cells were treated with the extracted basolateral EVs, and inflammatory cytokines and fibrosis markers were detected by RT-PCR. Highly expressed proteins from stimulated EVs were identified, and M1-macrophages, LX-2, KMST-6 were treated with these recombinant proteins. Stimulated EVs increased the expression of TNF, IL-1β, and IL-6 in M1-macrophages, TGF-β in LX-2 and KMST-6 compared with the corresponding expression levels in unstimulated EVs. Nucleophosmin, nucleolin, and midkine levels were increased in EVs from stimulated cells compared with protein expression in EVs from unstimulated cells. Leukocyte cell-derived chemotaxin-2 (LECT2) is highly expressed only in EVs from stimulated cells. Stimulation of M1-macrophages with recombinant nucleophosmin, nucleolin, and midkine significantly increased the expression of inflammatory cytokines. Stimulation of LX-2 and KMST-6 with recombinant LECT2 significantly increased the expression of fibrotic markers. These results suggest that basolateral EVs are related to the development of pericholangitis and periductal fibrosis in cholestatic liver diseases.NEW & NOTEWORTHY Our research elucidated that the composition of basolateral EVs from the biliary epithelial cells changed under bile acid exposure and the basolateral EVs contained the novel inflammation-inducing proteins NPM, NCL, and MK and the fibrosis-inducing protein LECT2. We report that these new results are possible to lead to the potential therapeutic target of cholestatic liver diseases in the future.
Interrupting transmission events is critical to tuberculosis control. Cough-generated aerosol cultures predict tuberculosis transmission better than microbiological or clinical markers. We hypothesize that highly infectious individuals with pulmonary tuberculosis (positive for cough aerosol cultures) have elevated inflammatory markers and unique transcriptional profiles compared to less infectious individuals. We performed a prospective, longitudinal study using cough aerosol sampling system. We enrolled 142 participants with treatment-naïve pulmonary tuberculosis in Kenya and assessed the association of clinical, microbiologic, and immunologic characteristics with Mycobacterium tuberculosis aerosolization and transmission in 129 household members. Contacts of the forty-three aerosol culture-positive participants (30%) are more likely to have a positive interferon-gamma release assay (85% vs 53%, P = 0.006) and higher median IFNγ level (P < 0.001, 4.28 IU/ml (1.77-5.91) vs. 0.71 (0.01-3.56)) compared to aerosol culture-negative individuals. We find that higher bacillary burden, younger age, larger mean upper arm circumference, and host inflammatory profiles, including elevated serum C-reactive protein and lower plasma TNF levels, associate with positive cough aerosol cultures. Notably, we find pre-treatment whole blood transcriptional profiles associate with aerosol culture status, independent of bacillary load. These findings suggest that tuberculosis infectiousness is associated with epidemiologic characteristics and inflammatory signatures and that these features may identify highly infectious persons.
PURPOSE: As a minimally invasive procedure, laser hemorrhoidoplasty (LHP) can not only relieve the symptoms of hemorrhoids, but also protect the anal cushion structure. This study aimed to investigate the clinical efficacy of LHP in the treatment of grade II hemorrhoids.
METHODS: A total of 70 patients with grade II hemorrhoids were randomly assigned to receive LHP or Rubber Band Ligation (RBL) (n = 35 per group) in 2019 from a single center. The postoperative pain, bleeding, feeling of anal distension(local falling, swelling, foreign body sensation, stool) and postoperative recurrence rate were compared between the two groups.
RESULTS: The postoperative pain, bleeding, and feeling of anal distension in the LHP group were improved significantly as compared with the RBL group within 2 weeks after surgery (P < 0.01). Both methods can relieve the symptoms of grade II hemorrhoids. There was no difference in the recurrence rate between the two groups at 1 year after surgery (P > 0.05). The patients in LHP group took less time to return to normal activities (P < 0.001).
CONCLUSIONS: As a minimally invasive treatment, LHP is easy and not traumatic and results in mild postoperative pain and few complications. It is an ideal choice for grade II hemorrhoids.
C9orf72 genetic mutation is the most common genetic cause of ALS/FTD accompanied by abnormal protein insufficiency. Induced pluripotent stem cell (iPSC)-derived two-dimensional (2D) and three-dimensional (3D) cultures are providing new approaches. Therefore, this study established neuronal cell types and generated spinal cord organoids (SCOs) derived from C9orf72 knockdown human iPSCs to model ALS disease and screen the unrevealed phenotype. Wild-type (WT) iPSC lines from three healthy donor fibroblasts were established, and pluripotency and differentiation ability were identified by RT-PCR, immunofluorescence and flow cytometry. After infection by the lentivirus with C9orf72-targeting shRNA, stable C9-knockdown iPSC colonies were selected and differentiated into astrocytes, motor neurons and SCOs. Finally, we analyzed the extracted RNA-seq data of human C9 mutant/knockout iPSC-derived motor neurons and astrocytes from the GEO database and the inflammatory regulation-related genes in function and pathways. The expression of inflammatory factors was measured by qRT-PCR. The results showed that both WT-iPSCs and edited C9-iPSCs maintained a similar ability to differentiate into the three germ layers, astrocytes and motor neurons, forming SCOs in a 3D culture system. The constructed C9-SCOs have features of spinal cord development and multiple neuronal cell types, including sensory neurons, motor neurons, and other neurons. Based on the bioinformatics analysis, proinflammatory factors were confirmed to be upregulated in C9-iPSC-derived 2D cells and 3D cultured SCOs. The above differentiated models exhibited low C9orf72 expression and the pathological characteristics of ALS, especially neuroinflammation.
Loop diuretics are generally first line therapy in patients hospitalized with acute heart failure syndrome (AHFS). Their use far exceeds that of vasoactive agents. Tubuloglomerular feedback (TGF) is the body's compensatory response to avoid excess fluid loss, and it is activated when elevated sodium concentrations in the distal tubule are detected. TGF is proposed as a contributing factor for the observed diuretic resistance that occurs in patients with heart failure. Higher doses of diuretics are required to overcome the decreased natriuresis and reduced RBF induced by TGF. Ultimately, this action creates a vicious cycle of worsening renal function and diminished diuretic effectiveness.

The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its mechanism of action as an adenosine A1 receptor antagonist. TGF promotes release of adenosine, and adenosine binding to A1 receptors causes vasoconstriction of the afferent arteriole, decreased RBF, and enhanced sodium reabsorption by the proximal tubule. This action results in a decrease in GFR, diminished renal function, and sodium and water retention. Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may limit sodium reabsorption by the proximal tubules without triggering TGF. It promotes vasodilation of the afferent arteriole of the glomerulus, and thus, this strategy offers the potential to overcome diuretic resistance or enhance diuretic responsiveness. It may also reduce the need for increasing diuretic doses that have been associated with worse outcomes.
The present invention discloses the application of bamboo-leaf total flavone in medicines and health foods thereof for preventing and treating prostate diseases. The bamboo-leaf total flavone is applied to medicines for preventing and treating prostate diseases and health foods. The present invention provides a safe, effective, economical and applicable plant extract namely the bamboo-leaf total flavone with wide sources. Systematic researches on the relevant characteristics of the bamboo-leaf total flavone to prostate pathology indicate that the bamboo-leaf total flavone has notable functions of resisting bacteria, resisting inflammation, resisting hyperplasia of prostate, resisting platelet aggregation, resisting tumors, promoting immunity, etc. A large quantity of previous researches indicate that the bamboo-leaf total flavone has the advantages of excellent physiological and pharmacological activity of resisting free radicals, oxidation and radiation, protecting heart blood vessels and brain blood vessels, etc., safety, no toxicity, no side effect after being used for a long term, stable performance and fragrant flavor. The bamboo-leaf total flavone can be prepared into various preparations and can also be compounded with multiple medicines and food systems; the bamboo-leaf total flavone is convenient in use and is especially suitable for preventing and treating senile chronic degenerative diseases with multiple target sites, such as prostate diseases.
It was planned to give "Cervical Cancer Education and Information Booklet" to the women in the control group about cervical cancer. Health Belief Model Scale for Cervical Cancer and Pap Smear Test: Psychometric testing was planned to be applied before and after the standard education and booklet in terms of outcome variables at 3 and 6 months.
BACKGROUND: Polycystic liver disease (PLD) is a common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Bile acids may play a role in PLD pathogenesis. We performed a post-hoc exploratory analysis of bile acids in ADPKD patients, who had participated in a trial on the effect of a somatostatin analogue. Our hypothesis was that serum bile acid levels increase in PLD, and that lanreotide, which reduces liver growth, may also reduce bile acid levels. Furthermore, in PLD, urinary excretion of bile acids might contribute to renal disease.
METHODS: With liquid chromatography-mass spectrometry, 11 bile acids in serum and 6 in urine were quantified in 105 PLD ADPKD patients and 52 age-, sex-, mutation- and eGFR-matched non-PLD ADPKD patients. Sampling was done at baseline and after 120 weeks of either lanreotide or standard care.
RESULTS: Baseline serum levels of taurine- and glycine-conjugated bile acids were higher in patients with larger livers. In PLD patients, multiple bile acids decreased upon treatment with lanreotide but remained stable in untreated subjects. Changes over time did not correlate with changes in liver volume. Urine bile acid levels did not change and did not correlate with renal disease progression.
CONCLUSION: In ADPKD patients with PLD, baseline serum bile acids were associated with liver volume. Lanreotide reduced bile acid levels and has previously been shown to reduce liver volume. However, in this study, the decrease in bile acids was not associated with the change in liver volume.
Athletes of teams at the 12U and 13U level pilot testing the intervention program. On-field activity will be monitored with head impact sensors and video to evaluate the effectiveness of the intervention program.
Esophageal squamous cell carcinoma (ESCC) is a common type of esophageal carcinoma in China, which is characterized by rapid development and fatal prognosis in most patients. Neoadjuvant chemoradiotherapy (nCRT) has been explored for many years in western countries and Japan, and proved to get survival benefit, especially for locally advanced esophageal cancer. However, the recurrence is the major cause of treatment failure in patients with ESCC. Our hypothesis is that inadequate radiation dose leads to recurrence of ESCC with nCRT and PORT lower recurrence rate and improved OS. As is known, there are no any studies concentrating on PORT in ESCC with nCRT. Patients are randomly assigned to PORT (Group A) or without PORT (Group B) with a 1:1 allocation ratio. The primary outcome is OS assessed with a minimum follow-up of 60 months. Secondary outcomes are progression-free survival (PFS), recurrence-free survival (RFS).
The parotids have not been traditionally considered an organ at risk / avoidance structure in whole brain radiation. However, patients receiving whole brain radiation sometimes complain of dry mouth. Investigators hypothesize that standard whole brain radiation fields cause an acute measurable increase in xerostomia at one month post-radiation, and that the severity of xerostomia is related to the dose received by the parotids. In this study, investigators will use the validated University of Michigan Xerostomia Questionnaire to prospectively collect baseline and post-radiation xerostomia scores up to 6 months after treatment. The radiation dose to the parotids will be evaluated to assess whether there is a dose-toxicity relationship. Investigators anticipate a total accrual of 60 patients with a goal of 48 evaluable patients.
OBJECTIVE: As metabolic dysfunction-associated steatotic liver disease (MASLD) becomes more prevalent worldwide, it is imperative to create more accurate technologies that make it easy to assess the liver in a point-of-care setting. The aim of this study is to test the performance of a new software tool implemented in Velacur (Sonic Incytes), a liver stiffness and ultrasound attenuation measurement device, on patients with MASLD. This tool employs a deep learning-based method to detect and segment shear waves in the liver tissue for subsequent analysis to improve tissue characterization for patient diagnosis.
METHODS: This new tool consists of a deep learning based algorithm, which was trained on 15,045 expert-segmented images from 103 patients, using a U-Net architecture. The algorithm was then tested on 4429 images from 36 volunteers and patients with MASLD. Test subjects were scanned at different clinics with different Velacur operators. Evaluation was performed on both individual images (image based) and averaged across all images collected from a patient (patient based). Ground truth was defined by expert segmentation of the shear waves within each image. For evaluation, sensitivity and specificity for correct wave detection in the image were calculated. For those images containing waves, the Dice coefficient was calculated. A prototype of the software tool was also implemented on Velacur and assessed by operators in real world settings.
RESULTS: The wave detection algorithm had a sensitivity of 81% and a specificity of 84%, with a Dice coefficient of 0.74 and 0.75 for image based and patient-based averages respectively. The implementation of this software tool as an overlay on the B-Mode ultrasound resulted in improved exam quality collected by operators.
CONCLUSION: The shear wave algorithm performed well on a test set of volunteers and patients with metabolic dysfunction-associated steatotic liver disease. The addition of this software tool, implemented on the Velacur system, improved the quality of the liver assessments performed in a real world, point of care setting.
A pharmacologically active composition which is suitable for use in palliative cancer therapy and as an agent having a muscle-relaxing and/or analgetic effect in neurological diseases. Said composition contains at least 80 wt. %, preferably 90 wt. %, tetrahydrocannabinol (THC) and cannabidiol (CBD), in relation to the overall weight of cannabinoids present therein. The weight ratio of THC to CBD=75:25-20:80, preferably 3:1-1:2, and especially 2:1. Said composition can be used for the production of pharmacologically effective agents which can be used in palliative cancer therapy and in the treatment of neurological diseases.
PURPOSE:To produce a membrane having a liquid active material, which can release the liquid active material at a constant rate over a long period of time, by coating the surface of a support with a soln. obtd. by dissolving a polymer and an active material, which is a liquid at room temp., in a specified org. solvent and then evaporating the solvent. CONSTITUTION:At least 30wt% polymer (A) such as PS and not more than 70wt% active material (B) (e.g. diazinon), which is a liquid at room temp. and has a solubility of not more than 5pts.wt. per 100pts.wt. polymer at room temp., are dissolved in an org. solvent (e.g. chloroform) in such a proportion as to give a concn. of 10-40wt% in term s of the combined quantity of components A and B, said solvent being capable of dissolving components A and B and being more volatile than component B. The resulting soln. is applied to the surface of a support in a coating thickness of 10-50mu and evaporated by heating at 0-100 deg.C, but at a temp. not higher than the b.p. of the solvent in an atmosphere having humidity of 60% or above to form a polymer layer in which component B in the formh of liquid droplet is enclosed in a lot of micropores which have a pore size of 0.5-10mu and are divided by a partition wall of 0.5-10mu in thickness.
PROBLEM TO BE SOLVED: To obtain the subject composition excellent in opacifying properties and abrasion resistance, free from stickiness and stiffness and capable of dyeing hair without causing color shading by compounding a specific pigment with a gelling agent and a film-forming polymer at a specific ratio. SOLUTION: This composition comprises (A) 2-40 wt.% pigment having pearly luster, (B) 0.1-5 wt.% gelling agent and (C) 0.2-5 wt.% film-forming polymer. The composition preferably further is compounded with a nonionic surfactant having 12-18 HLB value in an amount of 0.1-5 wt.% based on total amount of the composition. Mica titanium, mica titanium coated with a colored pigment such as carmine, iron blue or ultramarine blue pigment, etc., is preferably used as the component A. For example, carboxyvinyl polymer, polyacrylic acid amide, etc., is exemplified as the component B. Especially, a nonionic polymer compound is preferably used as the component C. Thereby, excellent hair mascara composition can be provided.